HMF Intensive 50 is a shelf-stable probiotic formula that offers 50 billion CFU from a combination of four proprietary strains. These microorganisms have been used in a wide body of clinical research and are one of the most studied probiotic combinations worldwide. Research has demonstrated that these strains support healthy gut flora and promote gastrointestinal comfort.
In addition, these human-sourced strains were selected based on their high quality and viability, strong epithelial adherence, and naturally high tolerance to stomach and bile acid.7 To further enhance probiotic survivability through the stomach, HMF Intensive 50 is produced with delayed-release capsules.
Each capsule is formulated with unique polymer properties that resist stomach acid and delay the release of probiotics after swallowing, allowing for a complete, targeted release in the intestines and optimal probiotic activity.
Delayed-release, shelf-stable probiotic formula
- Supports gastrointestinal health
- Provides 50 billion CFU per dose from a combination of four proprietary strains
- Formulated with acid-resistant and delayed-release capsules for targeted delivery to the intestines
- Convenient, once-daily capsule format
Probiotic Consortium - 50 billion CFU
Lactobacillus acidophilus (CUL-60 & CUL-21) - 38 billion CFU
Bifidobacterium animalis subsp. lactis (CUL-34) & Bifidobacterium bifidum (CUL-20) - 12 billion CFU
Delayed-release capsule (hypromellose, gellan gum), cellulose, stearic acid, silica.
Adults, Adolescents and Children (6 years and older): Take one capsule daily with a meal, at least two to three hours before or after taking antibiotics, or as recommended by your healthcare practitioner.
Consult a health care practitioner prior to use if you have fever, vomiting, bloody diarrhea or severe abdominal pain. If symptoms of digestive upset (e.g. diarrhea) occur, worsen, or persist beyond 3 days, discontinue use and consult a health care practitioner.
Do not use this product if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment).